We’re pleased to share a second initiative in partnership with @MichaelJFoxOrg and @KU_Leuven , focusing on innovative treatments for Parkinson’s disease. This project targets ATP10B, a gene linked to neurodegenerative conditions. Our Quantitative #AI models are screening for activators of ATP10B, accelerating the development of potential new therapies. Together with MJFF and KU Leuven, we’re advancing a new approach to AI-powered #DrugDiscovery for neurodegeneration. Read the full announcement: https://bit.ly/4fs7Bl7
#ParkinsonsResearch #AI #LifeSciences